Julienne (Julie) Vaillancourt is a pharmacist and a captain in the United States Public Health Service Commissioned Corps (US PHS CC). Since mid-2015, she has served as a policy advisor in the Office of the Director at the US Food and Drug Administration’s Center for Biologics Evaluation and Research (FDA/CBER) and serves as the Center’s Rare Disease Liaison. In this role she coordinates CBER’s Rare Disease Program, facilitates collaboration across CBER, with rare disease partners at FDA, and with external stakeholders including patient advocacy organizations on multiple rare disease-related efforts and issues, and contributes to relevant policy development at FDA. She is a graduate of Massachusetts College of Pharmacy (Boston) and Boston University School of Public Health. She worked as a pharmacist in New England for several years, before starting her career as a US PHS CC officer in 1995, in FDA/CBER’s Office of Vaccines Research and Review (OVRR), first as a Regulatory Project Manager (RPM) and later as an RPM Team Leader. There she served on several review teams for biologics license applications (BLAs) and Investigational New Drug Applications (INDs) for vaccines and related products. As a US PHS CC officer, she also served as an Emergency Health Consultant at the US Agency for International Development from 1999-2001, having returned to FDA/CBER afterward.